KDM5B and prostate carcinoma: Since Lu et al. reported that PLU-1 was highly expressed in breast cancer [28], several reports relevant to dysregulation of KDM5B in bladder cancer [27], breast cancer [29], lung cancer [27], neuroblastoma [30], prostate cancer [31] and others [32] have been reported.